GlassScriptPhysician profile
Brian R Toy
NPI 1720136823
$12,583.69
in general payments reported to CMS, 2019-2025
31 companies · $1,828 in 2025
The $1,828 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,791 · 2020: $1,207 · 2021: $842 · 2022: $1,525 · 2023: $2,025 · 2024: $2,367 · 2025: $1,828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,839 · Education: $380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,839.34 |
| Education | $380.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,238.79 | 2019-2025 | |
| Janssen Biotech, INC. | $1,539.70 | 2019-2025 | Tremfya, Simponi, Stelara |
| Incyte Corporation | $1,532.12 | 2021-2025 | Opzelura |
| Abbvie INC. | $1,330.21 | 2019-2025 | Skyrizi, Rinvoq |
| Pfizer INC. | $897.73 | 2019-2025 | |
| Lilly USA, LLC | $814.69 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $769.90 | 2021-2025 | |
| Leo Pharma INC. | $658.93 | 2019-2025 | Adbry |
| Regeneron Healthcare Solutions, INC. | $457.04 | 2019-2025 | Dupixent |
| Galderma Laboratories, L.P. | $427.92 | 2019-2025 | Nemluvio |
| E.R. Squibb & Sons, L.L.C. | $279.39 | 2022-2025 | Sotyktu |
| Regeneron Pharmaceuticals, INC. | $179.13 | 2023-2024 | Eylea, Eylea Hd |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $174.18 | 2019-2020 | |
| Ucb, INC. | $162.61 | 2024-2025 | Bimzelx |
| Sanofi-Aventis U.S. LLC | $159.52 | 2020-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $121.63 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $112.17 | 2023 | Xipere |
| Almirall LLC | $110.80 | 2019-2025 | Seysara, Klisyri |
| Mayne Pharma Commercial LLC | $105.26 | 2019-2024 | |
| Dermira, INC. | $86.84 | 2019-2021 | |
| Vyne Pharmaceuticals INC. | $70.96 | 2020 | |
| Medtronic, INC. | $69.40 | 2024 | Corevalve Evolut R |
| Genentech, INC. | $65.10 | 2019 | |
| Prugen, INC. Pharmaceuticals | $49.61 | 2020 | |
| Botanix Sb INC | $42.27 | 2025 | Sofdra |
| Amgen INC. | $38.16 | 2020-2021 | |
| Arcutis Biotherapeutics, INC. | $31.88 | 2023-2024 | Zoryve |
| Taro Pharmaceuticals USA, INC. | $17.05 | 2019 | |
| Aclaris Therapeutics, INC. | $14.65 | 2019 | |
| Journey Medical Corporation | $14.61 | 2024 | |
| Sandoz INC. | $11.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Toy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.